Literature DB >> 29580660

CKD Self-management: Phenotypes and Associations With Clinical Outcomes.

Sarah J Schrauben1, Jesse Y Hsu2, Sylvia E Rosas3, Bernard G Jaar4, Xiaoming Zhang2, Rajat Deo5, Georges Saab6, Jing Chen7, Swati Lederer8, Radhika Kanthety9, L Lee Hamm7, Ana C Ricardo10, James P Lash10, Harold I Feldman11, Amanda H Anderson2.   

Abstract

BACKGROUND: To slow chronic kidney disease (CKD) progression and its complications, patients need to engage in self-management behaviors. The objective of this study was to classify CKD self-management behaviors into phenotypes and assess the association of these phenotypes with clinical outcomes. STUDY
DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Adults with mild to moderate CKD enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. 3,939 participants in the CRIC Study recruited between 2003 and 2008 served as the derivation cohort and 1,560 participants recruited between 2013 and 2015 served as the validation cohort. PREDICTORS: CKD self-management behavior phenotypes. OUTCOMES: CKD progression, atherosclerotic events, heart failure events, death from any cause. MEASUREMENTS: Latent class analysis stratified by diabetes was used to identify CKD self-management phenotypes based on measures of body mass index, diet, physical activity, blood pressure, smoking status, and hemoglobin A1c concentration (if diabetic); Cox proportional hazards models.
RESULTS: 3 identified phenotypes varied according to the extent of implementation of recommended CKD self-management behaviors: phenotype I characterized study participants with the most recommended behaviors; phenotype II, participants with a mixture of recommended and not recommended behaviors; and phenotype III, participants with minimal recommended behaviors. In multivariable-adjusted models for those with and without diabetes, phenotype III was strongly associated with CKD progression (HRs of 1.82 and 1.49), death (HRs of 1.95 and 4.14), and atherosclerotic events (HRs of 2.54 and 1.90; each P < 0.05). Phenotype II was associated with atherosclerotic events and death among those with and without diabetes. LIMITATIONS: No consensus definition of CKD self-management; limited to baseline behavior data.
CONCLUSIONS: There are potentially 3 CKD self-management behavior phenotypes that distinguish risk for clinical outcomes. These phenotypes may inform the development of studies and guidelines regarding optimal self-management.
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CKD progression: cardiovascular outcomes; Chronic renal failure; all-cause death; atherosclerotic events; blood pressure control; chronic kidney disease (CKD); diabetes; healthy behaviors; heart failure; modifiable risk factors; patient engagement; self-care; self-management; smoking

Mesh:

Year:  2018        PMID: 29580660      PMCID: PMC6109611          DOI: 10.1053/j.ajkd.2018.01.047

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  52 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Development of a brief test to measure functional health literacy.

Authors:  D W Baker; M V Williams; R M Parker; J A Gazmararian; J Nurss
Journal:  Patient Educ Couns       Date:  1999-09

Review 3.  Self-management in patients with end stage renal disease: exploring domains and dimensions.

Authors:  Roberta Braun Curtin; Donna Mapes; Dori Schatell; Sally Burrows-Hudson
Journal:  Nephrol Nurs J       Date:  2005 Jul-Aug       Impact factor: 0.959

4.  Application of Latent Class Analysis to Identify Behavioral Patterns of Response to Behavioral Lifestyle Interventions in Overweight and Obese Adults.

Authors:  Stephanie L Fitzpatrick; Janelle W Coughlin; Lawrence J Appel; Crystal Tyson; Victor J Stevens; Gerald J Jerome; Arlene Dalcin; Phillip J Brantley; Felicia Hill-Briggs
Journal:  Int J Behav Med       Date:  2015-08

5.  Body mass index and the risk of development of end-stage renal disease in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Kozen Kinjo; Taku Inoue; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

6.  Obesity and change in estimated GFR among older adults.

Authors:  Ian H de Boer; Ronit Katz; Linda F Fried; Joachim H Ix; Jose Luchsinger; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum
Journal:  Am J Kidney Dis       Date:  2009-09-25       Impact factor: 8.860

7.  Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.

Authors:  Melanie K Haroun; Bernard G Jaar; Sandra C Hoffman; George W Comstock; Michael J Klag; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

8.  The effects of weight loss on renal function in patients with severe obesity.

Authors:  Avry Chagnac; Tali Weinstein; Michal Herman; Judith Hirsh; Uzi Gafter; Yaacov Ori
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

9.  Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

Authors:  James P Lash; Alan S Go; Lawrence J Appel; Jiang He; Akinlolu Ojo; Mahboob Rahman; Raymond R Townsend; Dawei Xie; Denise Cifelli; Janet Cohan; Jeffrey C Fink; Michael J Fischer; Crystal Gadegbeku; L Lee Hamm; John W Kusek; J Richard Landis; Andrew Narva; Nancy Robinson; Valerie Teal; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

10.  Cognitive function and self-care management in older patients with heart failure.

Authors:  Karen Harkness; George A Heckman; Noori Akhtar-Danesh; Catherine Demers; Elizabeth Gunn; Robert S McKelvie
Journal:  Eur J Cardiovasc Nurs       Date:  2013-06-03       Impact factor: 3.908

View more
  11 in total

1.  Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.

Authors:  Jordana B Cohen; Sarah J Schrauben; Lei Zhao; Michael D Basso; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Zhaoqing Wang; Priyanka T Bhattacharya; Diana A Chirinos; Stuart Prenner; Payman Zamani; Dietmar A Seiffert; Bruce D Car; David A Gordon; Kenneth Margulies; Thomas Cappola; Julio A Chirinos
Journal:  JACC Heart Fail       Date:  2020-01-08       Impact factor: 12.035

2.  Developing and validating a prognostic prediction model for patients with chronic kidney disease stages 3-5 based on disease conditions and intervention methods: a retrospective cohort study in China.

Authors:  Min Zhang; Nuo Lei; Xian-Long Zhang; Yanmin Xu; Hui-Fen Chen; Li-Zhe Fu; Fang Tang; Xusheng Liu; Yifan Wu
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

3.  Mobile Health (mHealth) Technology: Assessment of Availability, Acceptability, and Use in CKD.

Authors:  Sarah J Schrauben; Lawrence Appel; Eleanor Rivera; Claudia M Lora; James P Lash; Jing Chen; L Lee Hamm; Jeffrey C Fink; Alan S Go; Raymond R Townsend; Rajat Deo; Laura M Dember; Harold I Feldman; Clarissa J Diamantidis
Journal:  Am J Kidney Dis       Date:  2020-12-09       Impact factor: 11.072

4.  Association of functional and structural social support with chronic kidney disease among African Americans: the Jackson Heart Study.

Authors:  Rasheeda K Hall; Clemontina A Davenport; Mario Sims; Cathleen Colón-Emeric; Tiffany Washington; Jennifer St Clair Russell; Jane Pendergast; Nrupen Bhavsar; Julia Scialla; Crystal C Tyson; Wei Wang; Yuan-I Min; Bessie Young; L Ebony Boulware; Clarissa J Diamantidis
Journal:  BMC Nephrol       Date:  2019-07-15       Impact factor: 2.388

5.  The interaction between self-care behavior and disease knowledge on the decline in renal function in chronic kidney disease.

Authors:  Yi-Chun Tsai; Shu-Li Wang; Hui-Ju Tsai; Tzu-Hui Chen; Lan-Fang Kung; Pei-Ni Hsiao; Shih-Ming Hsiao; Shang-Jyh Hwang; Hung-Chun Chen; Yi-Wen Chiu
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

6.  Patient activation and its association with symptom burden and quality of life across the spectrum of chronic kidney disease stages in England.

Authors:  Winnie Magadi; Courtney J Lightfoot; Katherine E Memory; Shalini Santhakumaran; Sabine N van der Veer; Nicola Thomas; Rachel Gair; Alice C Smith
Journal:  BMC Nephrol       Date:  2022-01-26       Impact factor: 2.388

7.  Self-management program for patients with chronic kidney disease (SMP-CKD) in Southern China: protocol for an ambispective cohort study.

Authors:  Wen-Wei Ouyang; Hui-Fen Chen; Xue-Yi Xu; Xian-Long Zhang; Li-Zhe Fu; Fang Tang; Ze-Huai Wen; Gaetano Marrone; Li-Chang Liu; Jing-Xia Lin; Xu-Sheng Liu; Yi-Fan Wu
Journal:  BMC Nephrol       Date:  2022-03-05       Impact factor: 2.388

Review 8.  Risk Factors for CKD Progression: Overview of Findings from the CRIC Study.

Authors:  Mary Hannan; Sajid Ansari; Natalie Meza; Amanda H Anderson; Anand Srivastava; Sushrut Waikar; Jeanne Charleston; Matthew R Weir; Jonathan Taliercio; Edward Horwitz; Milda R Saunders; Katherine Wolfrum; Harold I Feldman; James P Lash; Ana C Ricardo
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-11       Impact factor: 8.237

9.  Diabetes status modifies the efficacy of home-based kidney care for Zuni Indians in a randomized controlled trial.

Authors:  V Shane Pankratz; E Eunice Choi; Fares Qeadan; Donica Ghahate; Jeanette Bobelu; Robert G Nelson; Thomas Faber; Vallabh O Shah
Journal:  J Diabetes Complications       Date:  2020-10-09       Impact factor: 2.852

10.  Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study.

Authors:  Sarah J Schrauben; Jesse Y Hsu; Julie Wright Nunes; Michael J Fischer; Anand Srivastava; Jing Chen; Jeanne Charleston; Susan Steigerwalt; Thida C Tan; Jeffrey C Fink; Ana C Ricardo; James P Lash; Myles Wolf; Harold I Feldman; Amanda H Anderson
Journal:  Kidney Int Rep       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.